Navigation Links
Synvista Therapeutics' Alagebrium Shows Potential for use in Treating Diabetes-Related Gastrointestinal Complications
Date:10/25/2007

"We look forward to future research efforts to further elucidate the role of AGEs in gastrointestinal complications including diabetic intestinal dysfunction, diabetic enteropathy and diabetic gastroparesis and the role that alagebrium may play in those disease."

About Synvista Therapeutics

Synvista Therapeutics is a biopharmaceutical company developing small molecule drugs to treat and prevent cardiovascular disease and to treat nephropathy in people with diabetes. The Company has identified several product candidates that it believes represent novel approaches to some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. These compounds metabolize lipid peroxides and have the potential to limit myocardial damage subsequent to a myocardial infarction. The Company is developing a clinical diagnostic test, based on cardiovascular risk assessment, using Haptoglobin characterization, to identify patients at high risk for cardiovascular complications of diabetes.

Synvista Therapeutics also is developing alagebrium, a proposed breaker of AGEs for the treatment of diastolic heart failure. This disease represents a rapidly growing market of unmet medical need, particularly common among diabetic patients. Alagebrium has demonstrated relevant clinical activity in two Phase 2 clinical trials in heart failure, as well as in animal models of heart failure and nephropathy, among others. Alagebrium has been tested in approximately 1,000 patients in multiple Phase 1 and Phase 2 clinical trials, allowing Synvista Therapeutics to assemble a sizeable human safety database. For more information, please visit the Company's website at http://www.synvista.com.

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties in
'/>"/>

SOURCE Synvista Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... Nov. 20, 2014   Coqui RadioPharmaceuticals Corp. , ... U.S. commercial producer of Molybdenum-99 (Mo-99), is proud to ... INVAP to design its Medical Isotope Production Facility ... is the parent isotope of Technetium-99, which is used ... 2012, Congress passed legislation making it a national priority ...
(Date:11/21/2014)... --  Wellcentive , the industry leader in end-to-end ... today being named one of the four finalists ...  Sponsored by Intel, the world leader in computing ... companies developing leading-edge technology and unique approaches to ... Wellcentive,s Mason Beard , senior vice ...
(Date:11/21/2014)... 2014  Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX ... of $80,000,000 aggregate principal amount of 5.25% Convertible Senior ... offering within the United States . ... pursuant to Rule 144A under the Securities Act of ... granted the initial purchasers an option to purchase up ...
Breaking Medicine Technology:Coqui RadioPharmaceuticals Inks Deal With INVAP 2Wellcentive Named Finalist for 2014 Intel Innovation Award 2Wellcentive Named Finalist for 2014 Intel Innovation Award 3Lexicon Announces Pricing Of Convertible Senior Notes Offering 2Lexicon Announces Pricing Of Convertible Senior Notes Offering 3
... SWANTON, Vt ., May 7 This May, AllerAir ... their effort to spread Multiple Chemical Sensitivity Syndrome awareness.   , ... AllerAir will make chemical awareness tips ... www.allerair.com .  Additionally, their blogs and articles ...
... A post-hoc analysis of a Phase 3 safety study ... a lower incidence of nausea, vomiting and constipation when compared ... moderate to severe low-back or osteoarthritis pain.  These data will ... Annual Scientific Meeting of the American Pain Society (APS), and ...
Cached Medicine Technology:Multiple Chemical Sensitivities Are Real 2Multiple Chemical Sensitivities Are Real 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 2Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 3Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 4Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 5Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 6Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 7Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 8Data Comparing NUCYNTA(R) (tapentadol) Tablets to Oxycodone Immediate Release Tablets Presented at 2010 American Pain Society Annual Meeting 9
(Date:11/23/2014)... 2014 SWAccessControl.com's high quality access control ... the company has announced its new collection of power ... these high quality power suppliers. All the new models ... special offer lasts until Dec. 20, 2014. , SWAccessControl.com ... have been supporting it for a long time. It ...
(Date:11/23/2014)... Falls Church, VA (PRWEB) November 23, 2014 ... and TV Have in Common, **FDAnews On-Demand Webinar**, Dec. ... http://www.fdanews.com/TheFDAisWatchingOnDemand , The FDA’s focus on promotional ... ads. , Now they're looking at websites, ... , Mark the calendar for Thursday, Dec. 11, for ...
(Date:11/22/2014)... Greenville, SC (PRWEB) November 23, 2014 ... back to their communities. AlignLife experience rapid growth in ... upon a very unique opportunity. AlignLife of Simpsonville ... area AlignLife offices for their first annual Toy Drive. ... local charity they would support with this year's toy ...
(Date:11/22/2014)... A classic black prom dress will never go out of ... unveiled its new items of black prom gowns . ... big discount, up to 70% off. People throughout the world ... prom dresses, made with the best materials, can make wearers ... customers, the company provides these beautiful outfits in a huge ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
Breaking Medicine News(10 mins):Health News:Cheap Access Control Power Supplies Online Now at SWAccessControl.com, Special Offer Until Dec. 20, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 2Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 3Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 4Health News:FDAnews Announces The FDA is Watching: What Twitter, Tradeshows and TV Have in Common, On-Demand Webinar, Dec. 11, 2014 5Health News:Greenville Area AlignLife Offices Join Together for a Local Toy Drive 2Health News:New Black Prom Dresses from BellasDress.com 2
... The Cosmetic Bootcamp, LLC,announces that its annual marketing and ... will begin on Dec. 11, 2008. Despite a ... sponsorship.,According to program chair, Kenneth Beer MD, "We are ... for specialists both by the specialists,and industry." Dr. ...
... resource the necessary information to make an informed decision when ... , , LYNDHURST, N.J., Dec. ... city,s best otolaryngologist (and figuring out what an otolaryngologist is), ... if you,re not an MD, a DO or are certified ...
... Phase II Cancer Trials and the Company,s Other Clinical Programs All ... - Significant Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral ... - Company Enters into Loan Agreement for Up to ... TUSTIN, Calif., Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: ...
... PetFit(TM) Challenge Participant Shows Remarkable Quick Weight Loss Improvement , ... On January 20, Zeb, a 104 pound, 7-year-old, Labrador ... Hill,s PetFit(TM) Challenge participants. At Zeb,s recheck on ... lost 22 pounds and was now at 82 pounds. Dr. ...
... dry skin... much of the time with poor results. During Winter, ... the skin. , ... Denver, CO. (PRWEB) December 10, 2008 -- Winter ... across the country suffering from dry skin problems. According to estimates ...
... Global Med Technologies(R), Inc.,("Global Med" or the "Company") (OTC ... today announced that on,Tuesday, December 9, 2008, its board ... LLC ("VPC") whereby VPC proposed to acquire a,majority share ... proposal received is,as follows: , , ...
Cached Medicine News:Health News:Vitals Launches Free eBook to Help Consumers Find 'Dr. Right' 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 2Health News:Video: Combined Veterinary and Pet Owner Efforts Help Pet Lose Big 3Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 2Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 2Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 3Health News:Global Med Technologies(R) Inc. Receives Unsolicited Proposal From Victory Park Capital Advisors, LLC 4
Cholesterol FS. For determination of cholesterol in serum or plasma. Available with Calibrator: Trucal U and Controls: Trulab N, Trulab P Trulab L....
Intended for the quantitative determination of total cholesterol in serum. Reaction: Endpoint. Reaction complete within five minutes. Wavelength: 500 nm. Linearity: 700 mg/dL (18.1 mmol/L). Single st...
This 16-bit integrated and cooled system is a completely self contained unit built with a long list of standard features including all-electronic-variable transilluminator and EPI lighting....
... SE is a major upgrade ... of important physical and software ... operation and increase efficiency. The ... Generation" ACS:180. The productivity of ...
Medicine Products: